Why the study?
Is active human herpesvirus 6 (HHV-6) infection associated with relapsing-remitting multiple sclerosis and its exacerbations?
Is active human herpesvirus 6 (HHV-6) infection associated with relapsing-remitting multiple sclerosis and its exacerbations?
Answers are grounded in this paper and cite their sources.
Active HHV-6 infection is significantly more common in patients with relapsing-remitting multiple sclerosis compared to healthy donors and may be associated with clinical relapses.
BACKGROUND: Recent studies have focused on the relationship between human herpesvirus 6 (HHV-6) and multiple sclerosis (MS). OBJECTIVE: To analyze HHV-6 messenger RNA expression in patients with relapsing-remitting (RR) MS vs healthy blood donors (HBDs). DESIGN: One hundred fifty-four subjects were enrolled in the study: 105 patients with RRMS (32 in relapse) and 49 HBDs. Total DNA and messenger RNA were extracted from serum and blood samples, respectively, and analyzed by quantitative real-time reverse transcription-polymerase chain reaction for the detection of 3 HHV-6 immediate-early genes (U16/U17,U89/U90, and U94) and both HHV-6 variants (HHV-6A and HHV-6B). RESULTS: Active HHV-6 infection was detected in 16% of patients with RRMS vs 0% of HBDs (P = .003). Seven patients with RRMS with exacerbation had HHV-6 active replication, and the virus remained latent in only 1 of them. We did not find any statistically significant difference between HHV-6 active or latent infection for patients in remission (P = .12). Among patients with RRMS with HHV-6 active replication, viral load was higher when they experienced an acute attack than when in remission (P = .04). In those patients with RRMS who had an active infection only, HHV-6A was found. Cell-free HHV-6 DNA detected in serum samples confirmed the results. CONCLUSIONS: The results show that a subset of patients with RRMS experience HHV-6 active infection, and there likely is an association between the viral active replication and relapses; therefore, HHV-6 active infection may imply a greater risk of exacerbations in a subgroup of patients with RRMS.
No takes yet. Share an insight, caveat, or question.
Álvarez‐Lafuente et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: